CVI Holdings’s 2seventy bio TSVT Stock Holding History

CVI Holdings’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-128,839	Closed	-$1.7M	–	892
2022 Q2	$1.7M	Sell	128,839 -690,833	-84%	-$9.41M	0.12%	278
2022 Q1	$14M	Buy	+819,672	New	+$13.9M	0.92%	8

Other funds holding TSVT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

CVI Holdings's TSVT Position: Q3 2022 in Review

CVI Holdings sold out of 2seventy bio (TSVT) in Q3 2022, closing a stake of 128,839 shares — an estimated $1.7M sold.

CVI Holdings first reported a position in TSVT in Q1 2022 and held it in 2 quarters. The position peaked at $14M in Q1 2022. 133 funds tracked by Wall St. Rank hold TSVT as of Q3 2022.

CVI Holdings reported no remaining 2seventy bio position as of Q3 2022 after selling out during the quarter.
CVI Holdings sold 128,839 2seventy bio shares in Q3 2022, an estimated $1.7M.
CVI Holdings first reported a position in 2seventy bio in Q1 2022 and held it in 2 quarters.
CVI Holdings's 2seventy bio position peaked at $14M in Q1 2022.
133 funds tracked by Wall St. Rank held 2seventy bio as of Q3 2022.

Based on CVI Holdings's 13F filing for Q3 2022, filed 14 Nov 2022.